4.4 Article

Association of Cohort and Individual Substance Use With Risk of Transitioning to Drug Use, Drug Use Disorder, and Remission From Disorder: Findings From the World Mental Health Surveys

期刊

JAMA PSYCHIATRY
卷 76, 期 7, 页码 708-720

出版社

AMER MEDICAL ASSOC
DOI: 10.1001/jamapsychiatry.2019.0163

关键词

-

资金

  1. United States National Institute of Mental Health [R01 MH070884]
  2. John D. and Catherine T. MacArthur Foundation
  3. Pfizer Foundation
  4. US Public Health Service [R13-MH066849, R01-MH069864, R01 DA016558]
  5. Fogarty International Center [FIRCA R03-TW006481]
  6. Pan American Health Organization
  7. Eli Lilly and Company
  8. Ortho-McNeil Pharmaceutical Inc
  9. Bristol-Myers Squibb
  10. Australian National Health and Medical Research Council [1081984]
  11. National Health and Medical Research Council Senior Principal Research Fellowship [1135991]
  12. National Institute on Drug Abuse [R01 DA044170-02]
  13. Australian Government Department of Health and Ageing
  14. Argentinian Ministry of Health (Ministerio de Salud de la Nacion)
  15. State of Sao Paulo Research Foundation [03/00204-3]
  16. Ministry of Health
  17. National Center for Public Health Protection
  18. Ministry of Social Protection
  19. Center for Excellence on Research in Mental Health (at CES University)
  20. European Commission [QLG5-1999-01042, SANCO 2004123, EAHC 20081308]
  21. Ministerio de Ciencia y Tecnologia, Spain [SAF 2000-158-CE]
  22. Generalitat de Catalunya [2017 SGR 452, 2014 SGR 748]
  23. Fondo de Investigacion Sanitaria, Instituto de Salud Carlos III, Spain [FIS 00/0028]
  24. GlaxoSmithKline
  25. Japanese and European Funds through United Nations Development Group Iraq Trust Fund
  26. Israel National Institute for Health Policy and Health Services Research
  27. National Insurance Institute of Israel
  28. Japan Ministry of Health, Labour andWelfare [H13-SHOGAI-023, H14-TOKUBETSU-026, H16-KOKORO-013, H25-SEISHIN-IPPAN-006]
  29. Lebanese Ministry of Public Health
  30. National Institutes of Health/Fogarty International Center [R03 TW006481-01]
  31. Algorithm
  32. AstraZeneca
  33. Benta
  34. Bella Pharma
  35. Eli Lilly
  36. Glaxo Smith Kline
  37. Lundbeck
  38. Novartis
  39. OmniPharma
  40. Pfizer
  41. Phenicia
  42. Servier
  43. UPO
  44. National Institute of Psychiatry Ramon de la Fuente [INPRFMDIES 4280]
  45. National Council on Science and Technology [CONACyT-G30544-H]
  46. New Zealand Ministry of Health
  47. Health Research Council
  48. World Health Organization Geneva
  49. World Health Organization Nigeria
  50. Federal Ministry of Health in Abuja, Nigeria
  51. Health AMP
  52. Social Care Research AMP
  53. Development Division of the Public Health Agency
  54. National Institute of Health of the Ministry of Health of Peru
  55. European Economic Area Financial Mechanism [PL 0256]
  56. Norwegian Financial Mechanism
  57. Polish Ministry of Health
  58. US National Institute of Mental Health [R01-MH059575, RO1-MH61905]
  59. National Institute of Drug Abuse
  60. South African Department of Health
  61. Regional Health Authority of Murcia (Servicio Murciano de Salud)
  62. Fundacion para la Formacion e Investigacion Sanitarias of Murcia
  63. National Institute of Mental Health [U01-MH60220]
  64. RobertWood Johnson Foundation [044708]
  65. Brazilian Council for Scientific and Technological Development (CNPq) [307784/2016-9]
  66. Medical Research Council of South Africa
  67. World Health Organization Lebanon
  68. Alcohol Advisory Council
  69. University of Michigan
  70. Regional Health Authority of Murcia (Consejeria de Sanidad y Politica Social)
  71. Piedmont Region (Italy)
  72. Instituto de Salud Carlos III (CIBER) [CB06/02/0046, RETICS RD06/0011 REM-TAP]
  73. Substance Abuse and Mental Health Services Administration
  74. JohnWAlden Trust
  75. National Health and Medical Research Council of Australia [1081984] Funding Source: NHMRC

向作者/读者索取更多资源

ImportanceLimited empirical research has examined the extent to which cohort-level prevalence of substance use is associated with the onset of drug use and transitioning into greater involvement with drug use. ObjectiveTo use cross-national data to examine time-space variation in cohort-level drug use to assess its associations with onset and transitions across stages of drug use, abuse, dependence, and remission. Design, Setting, and ParticipantsThe World Health Organization World Mental Health Surveys carried out cross-sectional general population surveys in 25 countries using a consistent research protocol and assessment instrument. Adults from representative household samples were interviewed face-to-face in the community in relation to drug use disorders. The surveys were conducted between 2001 and 2015. Data analysis was performed from July 2017 to July 2018. Main Outcomes and MeasuresData on timing of onset of lifetime drug use, DSM-IV drug use disorders, and remission from these disorders was assessed using the Composite International Diagnostic Interview. Associations of cohort-level alcohol prevalence and drug use prevalence were examined as factors associated with these transitions. ResultsAmong the 90027 respondents (48.1% [SE, 0.2%] men; mean [SE] age, 42.1 [0.1] years), 1 in 4 (24.8% [SE, 0.2%]) reported either illicit drug use or extramedical use of prescription drugs at some point in their lifetime, but with substantial time-space variation in this prevalence. Among users, 9.1% (SE, 0.2%) met lifetime criteria for abuse, and 5.0% (SE, 0.2%) met criteria for dependence. Individuals who used 2 or more drugs had an increased risk of both abuse (odds ratio, 5.17 [95% CI, 4.66-5.73]; P<.001) and dependence (odds ratio, 5.99 [95% CI, 5.02-7.16]; P<.001) and reduced probability of remission from abuse (odds ratio, 0.86 [95% CI, 0.76-0.98]; P=.02). Birth cohort prevalence of drug use was also significantly associated with both initiation and illicit drug use transitions; for example, after controlling for individuals' experience of substance use and demographics, for each additional 10% of an individual's cohort using alcohol, a person's odds of initiating drug use increased by 28% (odds ratio, 1.28 [95% CI, 1.26-1.31]). Each 10% increase in a cohort's use of drug increased individual risk by 12% (1.12 [95% CI, 1.11-1.14]). Conclusions and RelevanceBirth cohort substance use is associated with drug use involvement beyond the outcomes of individual histories of alcohol and other drug use. This has important implications for understanding pathways into and out of problematic drug use.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.4
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据